Uncontrolled cellular growth is a hallmark of cancer, however, targeting the crucial rate-limiting step of cell growth - the synthesis of ribosomal RNA, has remained elusive as a potential cancer treatment. We have developed the first selective inhibitor of this process, CX-5461, which has shown huge potential to treat human blood cancers and is in clinical trial. This project will identify novel combination therapies centred on targeting ribosome synthesis to treat subclasses of human blood cancers that are incurable.
A/Prof Simon Harrison, Prof Ross Hannan, A/Prof Andrew Wei
Cancer Council Research Grant
Peter MacCallum Cancer Centre
$100,000 per annum